Domestic Gene Therapy Financing Rebounds with Nearly 50% Growth in 2025

　　【Pharmaceutical Network Industry Dynamics】In 2025, the gene therapy sector in China showed a recovery trend, with the financing market gradually warming up. Statistics revealed that there were approximately 19 publicly disclosed financing events in China’s gene therapy sector in 2025, covering fields such as small nucleic acids, immune cell therapy, stem cells, and oncolytic therapies, representing a year-on-year increase of 46%. In terms of financing scale, companies like Epigenic Therapeutics, Inc., RayzeBio, and YolTech Therapeutics received significant funding.
 

Epigenic announced on September 8, 2025, the completion of a $60 million Series B financing round. The proceeds from this round will primarily be used to support the ongoing clinical development of the epigenetic innovative drug EPI-003 for the functional cure of chronic hepatitis B and EPI-001 for the treatment of hypercholesterolemia. Additionally, the funds will also be utilized to rapidly advance multiple preclinical projects and further develop the technology platform, providing strong momentum for the company’s deep commitment to the field of epigenetic drug research and development.
 

Data shows that Epigenic Therapeutics, Inc. owns the proprietary EPIREG™ technology platform, which utilizes DNA methylation and histone modification to silence target genes with high efficiency, durability, and specificity. Compared to traditional gene-editing tools that cut DNA, this provides chronic disease patients with a safer and revolutionary innovative treatment option, effectively avoiding potential safety concerns associated with conventional gene editing.
 

On September 30, 2025, RuiZheng Gene announced the completion of its Series A financing round, raising a total of 75 million US dollars. Data shows that RuiZheng Gene is an innovative enterprise focused on the research and development of intracellular target drugs. Based on next-generation gene editing, RNA editing, and delivery technologies with excellent targeting capabilities, the company is committed to providing patients with innovative drugs and treatment solutions for severe or even life-threatening congenital genetic diseases and acquired diseases. The introduction of this Series A financing will further accelerate RuiZheng Gene's research and development progress in the fields of gene editing and RNA editing, promoting the clinical transformation of more innovative drugs.
 

In September 2025, YolTech Therapeutics announced the completion of a Series B financing round exceeding 300 million RMB. Data shows that YolTech Therapeutics has established a high-throughput gene editor mining and evolution platform, as well as an LNP delivery platform targeting different tissues and organs. Leveraging these platforms, the company developed globally proprietary efficient gene editing tools: YolCas, base editor YolBE, and the lipid nanoparticle delivery system Yol-LNPs. In 2024, YolTech’s self-developed YOLT-201 injection for treating ATTR amyloidosis became the first LNP-delivered in vivo gene editing drug to enter the registration clinical stage. Since then, the company has continued to expand its pipeline, with four in vivo gene editing drug pipelines now in clinical stages. These cover various major rare diseases and common indications such as transthyretin amyloidosis (ATTR), familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and thalassemia (β-Thalassemia)/sickle cell disease (SCD).
 

Industry insiders indicate that the diversified innovation in technological pathways within the gene therapy field has become the core support for the recovery of financing. Among them, ophthalmic gene therapy, with clear indications, a large patient base, and relatively controllable delivery challenges, has become a golden track crowded with capital investments. Companies such as Mengmou Bio, Xingmu Bio, Jinweike Bio, and Zhongyin Technology are all focusing on this area, covering various blinding diseases such as retinitis pigmentosa and macular degeneration, echoing the global wave of AAV vector ocular targeted applications.
 

The recovery in financing within the gene therapy sector is the result of the resonance of multiple factors, including policy, technology, and market. In the future, with the implementation of financing funds and the continuous advancement of clinical pipelines, China's gene therapy industry will witness more breakthrough achievements, offering new solutions for the treatment of difficult diseases.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.